CLSD - Clearside Biomedical Secures Canadian Approval for XIPERE as Suprachoroidal Treatment for Uveitic Macular Edema

2025-07-23 08:53:30 ET

DENVER, Colo., Jul 23, 2025 ( 247marketnews.com )- Clearside Biomedical (NASDAQ:CLSD) reported that Health Canada approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME) , marking a significant milestone in the company’s continued global expansion.

With this latest regulatory clearance, XIPERE is now approved in four global markets: the United States, Canada, Australia, and Singapore , with review currently underway in China. The approval not only validates Clearside’s innovative SCS injection platform but also continues to solidify the company’s presence in the international ophthalmology landscape.

XIPERE is a proprietary formulation of triamcinolone acetonide designed for suprachoroidal administration , specifically to treat macular edema associated with uveitis . It is administered using Clearside’s SCS Microinjector , a patented in-office device that enables targeted drug delivery to the back of the eye. XIPERE was the first therapy approved in the U.S. for suprachoroidal use and is commercially available through Bausch + Lomb , which holds exclusive rights in the U.S. and Canada.

The post Clearside Biomedical Secures Canadian Approval for XIPERE as Suprachoroidal Treatment for Uveitic Macular Edema appeared first on 24/7 MarketNews .

For further details see: